Efthymios Nikolaos Deliargyris, MD, FACC, FSCAI

21/5/2018

CURRICULUM VITAE Efthymios Nikolaos Deliargyris, MD, FACC, FSCAI

OFFICE ADDRESS: ATHENS MEDICAL CENTER Distomou 5-7, 15125, Athens, GREECE Tel: (0030) 210-6157023 Fax: (0030) 210-6106833

HEART & VASCULAR INSTITUTE of SOUTHERN ATHENS Vakhou 2, VARI 16672, Athens, GREECE Tel: (0030) 210-8976320-1 Fax: (0030) 210-8976322

e-mail: [email protected] , [email protected]

PERSONAL DATA: Birthdate & Place: 6/23/1968 – Thessaloniki, GREECE Citizenship: Greek Family status: Married, 2 children

CURRENT POSITIONS

Professional Director, Cardiology Clinic Athens Medical Center, Athens GREECE Interventional Cardiology, Athens Medical Center Director, Heart & Vascular Institute of Southern Athens

Academic: • Member, Fellowship Committee, European Association of Percutaneous Coronary Interventions (EAPCI) • Assistant Professor of Internal Medicine/Cardiology Director, Intravascular Ultrasound Wake Forest University School of Medicine

EDUCATION: Doctorate of Medicine. Kapodistrian University School of Medicine, Athens, GREECE, 1984-1991

ACADEMIC APPOINTMENTS

2001 - 2004 Assistant Professor (Tenured) in Medicine/Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC

1999 - Present Senior Research Associate, Center for Oral and Systemic Disease, Chapel Hill, NC

1997 - 2001 Instructor in Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

1 21/5/2018

POST-GRADUATE TRAINING 1991.1994 Post-Doctoral Research Fellow. Dept of Pharmacology and Experimental Therapeutics, Tufts University, Boston, MA 1994.1995 Internship - Internal Medicine. Newton-Wellesley Hospital, Tufts University, Boston, MA 1995.1997 Residency and Chief Residency - Internal Medicine. Newton- Wellesley Hospital, Tufts University, Boston, MA 1997.2000 Fellowship and Chief Fellowship - Cardiology. University of North Carolina at Chapel Hill 2000-2001 Interventional Cardiology Fellowship. University of North Carolina at Chapel Hill

CERTIFICATION & LICENSURE

Medical Licensure: Massachusetts, USA 1994 North Carolina, USA 1997 Athens, GREECE 2003

American Board of Internal Medicine (ABIM) Certification Candidate # 175314 1997 Internal Medicine 2000 Adult Cardiovascular Disease 2001 Interventional Cardiology

Educational Commission for Foreign Medical Graduates (ECFMG) ID # 0-460-323-9 Certificate # 9176E (valid indefinitely) January 1993 FMGEMS Part I July 1993 FMGEMS Part II December 1993 FLEX Part I & II

HONORS & AWARDS

2009 Scientific Committee, Global Cardiovascular Clinical Trialists Forum 2005 Champion Physician, SORIN Group 2005 Member, Scientific Medical Advisory Board (SCIMAB), Boston Scientific International 2003 Fellow, Society of Cardiac Angiography & Interventions (FSCAI) 2003 Fellow, American College of Cardiology (FACC) 2002 Vascular Biology Working Group Award for Cardiovascular Research 2001 AstraZeneca - David W. Haack Memorial Award in Cardiovascular Research 1999 The BRACCO Diagnostics Inc. / Society of Cardiac Angiography & Interventions Fellowship Award 1999 Chief Cardiology Fellow in Training, University of North Carolina School of Medicine 1998 Merck Lipid Young Investigator Award 1996 Chief Medical Resident, Newton-Wellesley Hospital, Tufts University School of Medicine 1992 UCB Research Grant. UCB Institute of Allergy, Brussels, Belgium 1984 United States Presidential Academic Excellence Award

2 21/5/2018

RESEARCH INVESTIGATIONS

INVESTIGATOR-GUIDED PROTOCOLS

Principal Investigator 1997 - 2000: Mast Cell Mediators in Coronary Artery Disease. 1998 - 2000: Mast Cell Mediators in Congestive Heart Failure. 1998 - 2001: Periodontal Disease and Acute Myocardial Infarction. 2001 – 2004: Safety of Abciximab Use During PCI in Patients With Prior Stroke. 2001 – 2004: Abciximab vs. Eptifibatide: Retrospective Database Review of Procedural, In-Hospital, 30-Day, and 6-Month PCI Outcomes. 2002 – 2003: Effect of Oral Thalidomide on Inflammatory Markers & Endothelial Function in Patients With Acute Coronary Syndromes. 2005 – Present: Relation of Periodontal With Subclinical Atherosclerosis 2006 – 2007 Safety of Closure Devices after PCI Using Angiographically Guided Landmarks 2007 – 2009 Patterns of Coronary Dominance Among Greek Adults 2007 – Present All-Comers PCI with Bilavirudin in Greece

Co-Investigator 2001 - 2003: Study of Coronary Artery Geometry Utilizing IVUS 2000 - 2001: Abciximab vs. Eptifibatide: Comparison of Anti-Platelet Effects in the Presence or Absence of Unfractionated Heparin. 1999 - 2001: Clot Signature Analyzer: Assessment of coagulation in PCI pts. 1999 - 2001: Periodontal Disease and Endothelial Function. 1995 - 1997: Coumadin and Aspirin Prevention Trial (CAPT).

INDUSTRY-SPONSORED CLINICAL TRIALS

Principal Investigator EMERALD Trial (2002) ACUITY Trial (2003) OLYMPIA Registry (2005) PROMETEUS Registry (2009) ENGAGE AF (2009)

Co-Investigator REVERSAL Trial (2001) SWING Trial (2001) X-TRACT: X-SIZER Trial (2001) SYNERGY Trial (2001) PRIDE Study (2001) DELIVER Trial (2001) TAXUS IV Trial (2002) ELECT Trial (2002) ACCUMETRICS (2002) TAXUS V (2003) ACTIVATE Trial (2003) GUARD Trial (2003)

GRANT SUPPORT

1. Project Title: Mast Cell Mediators in the Coronary Circulation Role: Principal Investigator Agency: Merck & Co. Inc. Amount: $ 85,212

3 21/5/2018

Period: 1/1/99 – 6/31/2001 – Completed

2. Project Title: Mast Cell Mediators in Coronary Artery Disease Role: Principal Investigator Agency: Bracco Diagnostics/Society of Cardiac Angiography & Interventions (SCA&I) Amount: $ 25,000 Period: 6/1/99 – 6/1/2001 – Completed

3. Project Title: Periodontal Disease & Acute Myocardial Infarction: Effect on CRP Levels Role: Principal Investigator Agency: Astra-Zeneca, “David W. Haack Award in Cardiovascular Research” Amount: $ 10,000 Period: 10/1/01 – 10/1/02 – Completed

4. Project Title: Coronary Artery Dynamic Geometry and Atherosclerosis Role: Co-Investigator Agency: NIH/NHLBI (R01 HL58856) Amount: $ 635,557 Period: 04/01/99 – 03/31/04 – Completed

5. Project Title: ReoPro Administration for PCI in Patients With Prior Stroke Role: Principal Investigator Agency: Eli-Lilly, Centocor Amount: $ 39,400 Period: 12/01/01 – 12/30/02 – Completed

6. Project Title: Effect of Thalidomide on Inflammatory Markers and Endothelial Function in Patients With Acute Coronary Syndromes Role: Principal Investigator Agency: Vascular Biology Working Group Amount: $ 25,000 Period: 11/02-11/03 - In Progress

7. Project Title: The HEPA-RISK Study – High Expression of Anti-Platelet Factor 4/Heparin Antibodies and RISK in PCI Role: Principal Investigator Agency: The Medicines Company Amount: $ 27,038 Period: Complete

9. Project Title: Abciximab vs. Eptifibatide: Retrospective Database Review of Procedural, In-Hospital, 30-Day, and 6-Month PCI Outcomes. Role: Principal Investigator Agency: Eli Lilly & Co. Amount: $ 56,250 Period: Complete

10. Project Title: Primary PCI with Bivalirudin & GP IIb/IIIa Inhibitors

4 21/5/2018

Role: Principal Investigator Agency: Galenica Pharmaceuticals Amount: € 15,000 Period: 2006 - Present

EDITORIAL & PEER-REVIEW PROJECTS

2002 - Present Editorial Board , American Journal of Cardiology

1999 - Present Reviewer, American Journal of Cardiology

2001 - Present Reviewer, Catheterization & Cardiovascular Interventions

2002 - Present Reviewer, Circulation

2002 - Present Reviewer, Coronary Artery Disease

2002 - Present Reviewer, International Journal of Cardiology

2003 - Present Reviewer, Journal of the American College of Cardiology (JACC)

2005 – Present Reviewer, Hellenic Journal of Cardiology

2001 - Present Question Writer, Cardiovascular Disease Certification Examinations - American Board of Internal Medicine

2002 - Present Consultant & Reviewer, European Community - Ministry for Tertiary Education

2002 - Present Consultant & Reviewer, Hellenic Ministry of Higher Education

POSTER PRESENTATIONS – PUBLISHED ABSTRACTS

1. Deliargyris EN, Theoharides TC. Differential Effects of Plant Flavonoids on Mast Cell Secretion. European Academy of Allery and Clinical Immunology 1993, p. 109, Rotterdam, The Netherlands.

2. Kanellopoulos AJ, Perry HD, Donnenfeld ED, Deliargyris EN. Comparison of Topical Timolol Gel to Oral Acetazolamide in the Prophylaxis of Viscoelastic Induced Ocular Hypertension after Penetrating Keratoplasty. Invest Opthalm & Vis Sci 1996; 37:(3) 2528.

3. Deliargyris EN, Kontos JL, Dehmer GJ, Boucher WS, Theoharides TC. Tryptase, a Novel Modulator of Fibrinogen Activity is Elevated in Patients with Coronary Artery Disease. Bl Coag Fibrinol 1999; 10 (suppl 1): S108.

5 21/5/2018

4. Deliargyris EN, Dehmer GJ, Tate DA, Smith Jr. SC, Boucher WS, Theoharides, TC. Elevated Levels of Mast Cell Mediators in the Coronary Circulation of Patients With Coronary Artery Disease. Atherosclerosis 1999; 144 (suppl-I): I-120.

5. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Smith Jr. SC, Dehmer GJ. Interleukin-6 Release in the Coronary Circulation of Patients With Acute Coronary Syndromes. Eur Heart J 1999; 20 (suppl): I-395.

6. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Elevated Serum Interleukin-6 Levels Are From Cardiac Sources in Acute Coronary Syndromes But Not in Congestive Heart Failure. Circulation 1999; 100 (suppl-I): I-372.

7. Deliargyris EN, Dehmer GJ. Mast Cell Mediators in Coronary Artery Disease. 23rd Scientific Sessions of the Society of Cardiac Angiography & Interventions. Charleston, SC, 2000.

8. Deliargyris EN, Raymond RS, Theoharides TC, Boucher WS, Pye JP, Smith Jr. SC, Dehmer GJ. Elevated Serum IL-6 Levels in Asymptomatic Left Ventricular Systolic Dysfunction. Eur Heart J 2000; 21 (suppl-I): I-664.

9. Deliargyris EN, GJ Dehmer, JP Pye, Smith Jr. SC, Boucher WS, Theoharides TC. Mast Cell Tryptase: A New Inflammatory Marker in Patients With Stable Coronary Artery Disease. Eur Heart J 2000; 21 (suppl-I): I-159.

10. Deliargyris EN, Raymond RS, Theoharides TC, Boucher WS, Pye JP, Smith Jr. SC, Dehmer GJ. Cytokine Production in Subclinical Left Ventricular Dysfunction. Eur J Heart Fail 2000; (suppl-I): I-9.

11. Deliargyris EN, Raymond RS, Theoharides TC, Pye JP, Boucher WS, Dehmer GJ. Elevated Serum IL-6 Levels in Patients With Asymptomatic Left Ventricular Dysfunction. Circulation 2000; 102 (suppl-II):II-781.

12. Deliargyris EN, Marron I, Kadoma W, Smith Jr. SC, Madianos P, Beck JD, Offenbacher S. Periodontal Disease and Acute Myocardial Infarction. Circulation 2000; 102 (suppl- II):II-710.

13. Deliargyris EN, Melton LG, Thompson CM, Fisher M, Gabriel DA, Dehmer GJ. Assessment of Global Hemostasis After GP IIb/IIIa Inhibition With and Without Heparin During Coronary Interventions. J Invas Cardiol 2001; 13:476.

14. Kadoma W, Marron I, Deliargyris EN, Riche E, Champagne CME, Madianos PN, Smith Jr SC, Beck JD, Offenbacher S. Periodontitis and C-Reactive Protein in Myocardial Infarction Patients. J Dental Res 2001; 80 (suppl):721.

15. Deliargyris EN, Kadoma W, Marron I, Madianos PN, Smith SC Jr., Beck JD, Offenbacher S. Effect of Periodontal Disease on C-Reactive Protein in Acute Myocardial Infarction. 7th AstraZeneca Cardiovascular Young Investigator’s Forum. Jackson Hole, WY – 2001.

16. Deliargyris EN, Melton LG, Thompson C, Fisher M, Gabriel DA, Dehmer GJ. Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab But Not Eptifibatide During Coronary Interventions. JACC 2002; 39 (suppl): 27A.

6 21/5/2018

17. Deliargyris EN, Melton LG, Thompson C, Fisher M, Gabriel DA, Dehmer GJ. Superior Platelet Inhibition With Eptifibatide Compared With Abciximab in Patients Receiving Unfractionated Heparin During Coronary Interventions. XIVth World Congress of Cardiology – JACC 2002.

18. Upadhya B, Kontos JL, Ardershipour F, Pye JP, Boucher WC, Theoharides TC, Dehmer GJ, Deliargyris EN. Mast Cell Tryptase is Not Elevated in Patients With Left Ventricular Systolic Dysfunction. J Heart Fail 2002; 7(1):72.

19. Upadhya B, Kontos JL, Sane DC, Applegate RJ, Kutcher MA, Riesmeyer JS, Deliargyris EN. Abciximab Use During PCI of All Patients With Prior Stroke is not Associated With an Increased Incidence of In-Hospital Stroke. Am J Cardiol 2002 ;TCT- 420:162H.

20. Deliargyris EN, Upadhya B, Sane DC. Abciximab vs. Eptifibatide: A Single Operator, Single Center Comparison of In-Hospital Outcomes in 493 Consecutive PCI. SCA&I 2003

21. Deliargyris EN, Upadhya B, Sane DC. Superior Clinical Outcomes With Abciximab vs. Eptifibatide: A Contemporary, Single Center, Single Operator, Non-Randomized Comparison of 500 Consecutive PCI.. ESC 2003

22. Applegate RJ, Sane DC, Deliargyris EN, Goodin JE, Grabarczyk MA, Baki TT, Gandhi SK, Kutcher MA.. Platelet Dynamics in Patients Switched from Eptifibatide to Abciximab at the Time of PCI. AHA 2003

23. Deliargyris EN, Upadhya B, Gandhi SK, Applegate RJ, Kutcher MA, Baki TT, Sane DC. Improved Myocardial Perfusion With Bivalirudin Compared to Heparin During Primary or Rescue Angioplasty With Glycoprotein IIb/IIIa Inhibitors. TCT 2003

24. Deliargyris EN, Upadhya B, Smith CH, Applegate RJ, Kutcher MA, Yoder M, Sane DC. Bivalirudin as a Replacement for Heparin in PCI – Experience in the “Real World”. TCT 2003

25. Deliargyris EN, Berry JL, Rolland PH, Mekkaoui C, Moore JE. A Novel Compliance Matching Design Improves the Hemodynamic and Mechanical Disturbances Associated With Stenting. ISET 2004

26. Upadhya B, Applegate RJ, Kutcher MA, Sane DC, Gandhi SK, Baki TT, Deliargyris EN. Differences in Baseline Characteristics and In-Hospital Outcomes in Patients With or Without a Prior Stroke Undergoing Percutaneous Coronary Intervention. TCT 2004

27. Papaioannou GI, Athar HDada MR, Patel SB, Deliargyris EN, Boden WE, Kiernan FJ, McKay RG. Predictors of Contrast Nephropathy in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Angioplasty. ESC 2005

28. Deliargyris EN, Papaioannou GI, Lambrou SG, Tsaousis GS, Tzinieris GN, Sane DS. Direct Thrombin Inhibition With Bivalirudin Results in Improved Myocardial Perfusion Compared With Heparin During Primary or Rescue Angioplasty. AICT-HJC 2005

7 21/5/2018

29. Tsaousis GS, Papaioannou GI, Lambrou SG,Triantafillos I, Tzinieris GN, Deliargyris EN. Closure of Intracardiac Communications in Adults with Cryptogenic Stroke: The Necessity of a Multidisciplinary Approach. AICT-HJC 2005

30. Deliargyris EN. Antiplatelet Therapy Following Drug Eluting Stent Implantation. Serb Cardiology Association 2007.

31. Deliargyris EN. Antithrombotic and Antiplatelet Considerations Following Drug Eluting Stent Implantation. SCIMAB 2007

32. Deliargyris EN. Long-Term Data With the TAXUS Drug Eluting Stent. AICT 2007.

33. Deliargyris EN, Sane DC. Direct Thrombin Inhibition With Bivalirudin Improves Myocardial Perfusion Compared With During Primary or Rescue Angioplasty With GP IIb/IIIa Inhibitors. J. Cor Artery Disease 2007; 023-6.

34. Tzinieris GN, Martzaklis VI, Billias DN, Deliargyris EN. Patterns of Coronary Dominance Among Greek Adults. ICE 2007

35. Tzinieris GN, Martzaklis VI, Hiotis PE, Billias DN, Deliargyris EN. Initial Hellenic Experience With Bivalirudin For Percutaneous Coronary Interventions. ICE 2007

8 21/5/2018

TEXTBOOK CHAPTERS

1. Deliargyris EN, Nesto RW. Autonomic Neuropathy and Heart Disease. In: Veves A, ed. Clinical Management of Diabetic Neuropathy. Humana Press, Totowa, NJ, 1998:209- 226.

2. McKee SA, Deliargyris EN. Acute Pericarditis. In: Physicians’ Infornation and Education Resourse (PIER). American College of Physicians. 2002

MANUSCRIPTS IN PEER-REVIEWED JOURNALS

1. Tolba KA, Deliargyris EN. Cardiotoxicity of Cancer Therapy. Cancer Investigation 1999; 17:408-422.

2. Deliargyris EN, Falsone JM, Willis IV PW. Pulmonary Embolus in Transit. Clin Cardiol 1999; 22: 673-674.

3. Deliargyris EN, Raymond RJ, Guzzo JA, Dehmer GJ, Smith Jr. SC, Weiner MS, Roberts CS. Preoperative Factors Predisposing to Early Postoperative Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting. Am J Cardiol 2000; 85:763-764.

4. Deliargyris EN, Raymond RJ, Theoharides TC, Boucher WS, Tate DA, Dehmer GJ. Sites of Interleukin-6 Release in Patients With Acute Coronary Syndromes and in Patients With Congestive Heart Failure. Am J Cardiol 2000; 86:913-918.

5. Deliargyris EN, Dehmer GJ. History Repeats Itself (letter). Circulation 2001; 103:e48.

6. Raymond RJ, Dehmer GJ, Theoharides, TC, Deliargyris, EN. Elevated Interleukin-6 Levels in Patients With Asymptomatic Mild to Moderate Left Ventricular Dysfunction. Am Heart J 2001; 141:435-438.

7. Deliargyris EN, Dehmer GJ, Willis IV, PW. Successful Medical Therapy of Left Main Thrombosis: Value of Serial Coronary Angiography. J Invas Cardiol 2001; 13(9):644-6.

8. Nichols TC, Fischer TH, Deliargyris EN, Baldwin Jr. AS. Role of NF- B in Inflammation, Periodontitis and Atherogenesis. Ann Periodontol 2001; 6:20-29.

9. Erwin MB, Deliargyris EN. Cocaine-Associated Chest Pain. Am J Med Sci 2002; 324:37- 44.

10. McKee SA, Sane DC, Deliargyris EN. Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance. Thrombosis & Haemostasis 2002; 88:711-15.

11. McKee SA, Roberts CS, Deliargyris EN. Successful Secondary Repair of Double-Outlet Right Ventricle With Sub-Aortic Ventricular Septal Defect and Pulmonary Atresia in Adulthood. Am J Cardiol 2003; 91:380-2.

9 21/5/2018

12. Williams, RT, Damaraju LV, Mascelli MA, Barnathan ES, Califf RM, Simoons ML, Deliargyris EN, Sane DC. Anti-platelet factor 4/heparin antibodies: An independent predictor of 30 day myocardial infarction following acute coronary syndromes. Circulation. 2003;107:2307-2312.

13. Upadhya B, Kontos JL, Ardeshirpour F, Pye J, Boucher WS, Theoharides TC, Dehmer GJ, Deliargyris EN . Relation of serum levels of mast cell tryptase of left ventricular systolic function, left ventricular volume or congestive heart failure. J Card Fail. 2004 Feb;10(1):31-5.

14. Erwin MB, Hoyle JR, Smith CH, Deliargyris EN . Cocaine and accelerated atherosclerosis: insights from intravascular ultrasound. Int J Cardiol. 2004 Feb;93(2-3):301-3.

15. Call JT, Deliargyris EN, Newby LK. Focusing on inflammation in the treatment of atherosclerosis. Cardiol Rev. 2004 Jul-Aug;12(4):194-200.

16. D eliargyris EN, Madianos PN, Kadoma W, Marron I, Smith SC Jr, Beck JD, Offenbacher S. Periodontal disease in patients with acute myocardial infarction: prevalence and contribution to elevated C-reactive protein levels. Am Heart J. 2004 Jun;147(6):1005-9.

17. Call JT, Deliargyris EN, Sane DC. Direct thrombin inhibitors in the treatment of immune- mediated heparin-induced thrombocytopenia. Semin Thromb Hemost. 2004 Jun;30(3):297-304.

18. Mascelli MA, Deliargyris EN , Damaraju LV, Barnathan ES, Sane DC. Role of anti- PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes. Semin Thromb Hemost. 2004 Jun;30(3):347-50.

19. Deliargyris EN , Upadhya B, Applegate RJ, Kutcher MA, Gandhi SK, Sane DC. Superior in- hospital and 30-day outcomes with abciximab versus eptifibatide: a contemporary analysis of 495 consecutive percutaneous coronary interventions. J Invasive Cardiol. 2004 Nov;16(11):611-6.

20. Smith CH, Erwin MB, Deliargyris EN. Tissue shearing with distal translocation complicating cutting balloon angioplasty during treatment of in-stent restenosis. J Invasive Cardiol. 2005 Jan;17(1):40-1.

21. Deliargyris EN , Upadhya B, Sane DC, Dehmer GJ, Pye J, Smith SC Jr, Boucher WS, Theoharides TC. Mast cell tryptase: a new biomarker in patients with stable coronary artery disease. Atherosclerosis. 2005 Feb;178(2):381-6.

22. Mascelli MA, Deliargyris EN , Damaraju LV, Barnathan ES, Califf RM, Simoons ML, Sane DC. Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. J Thromb Thrombolysis. 2004 Dec;18(3):171-5.

23. Tsoukas A, Martzaklis BI, Lamprou SG, Deliargyris EN. “Carabello Sign”: The Ultimate Hemodynamic Verification of Critical Aortic Stenosis. Heart & Vessels, Oct 2005

24. Upadhya B, Sane DC, Applegate RJ, Kutcher MA, Gandhi SK, Deliargyris EN . Differences in baseline characteristics and in-hospital outcomes in patients with or without prior

10 21/5/2018

stroke undergoing percutaneous coronary intervention. J Invasive Cardiol. 2005 May;17(5):243-7.

25. Deliargyris EN , Upadhya B, Applegate RJ, Kontos JL, Kutcher MA, Riesmeyer JS, Sane DC. Safety of abciximab administration during PCI of patients with previous stroke. J Thromb Thrombolysis. 2005 Jun;19(3):147-53.

26. Upadhya B, Applegate RJ, Sane DC, Deliargyris EN, Kutcher MA, Gandhi SK, Baki TT, Call JT, Little WC. Preprocedural white blood cell count and major adverse cardiac events late after percutaneous coronary intervention in saphenous vein grafts. Am J Cardiol. 2005 Aug 15;96(4):515-8.

27. Deliargyris EN, Upadhya B, Melton LG, Thompson C, Fisher M, Gabriel DA, Dehmer GJ, Sane DC. Unfractionated Heparin Reduces the Anti-Platelet Effects of Abciximab but not Eptifibatide During PCI. Clin Appl Thrombosis.Hemostasis 2006; 12(2):458-64.

28. Tzinieris IN, Papaioannou GI, Dragomanovits SI, Deliargyris EN. Minimizing Femoral Access Complications in Patients Undergoing Percutaneous Coronary Interventions: A Proposed Strategy of Bony Landmark Guided Femoral Access, Routine Access Site Angiography and Appropriate Use of Closure Devices. Hellenic J Cardiol. 2007;48(3):127-33.

29. Dragomanovits SI, Lazopoulos GL, Tzinieris IN, Deliargyris EN. Coronary Artery Disease Following Mediastinal Irradiation. Hellenic J Cardiol. 2007;48(3):181-3.

30. Deliargyris EN. Intravascular Ultrasound Virtual Histology Derived Thin Cap Fibroatheroma: Now You See it, Now You Don’t. J Am Coll Cardiol. 2009; In Press